SCHEMBL10177606

SCHEMBL10177606

O=C(O)CCCCO[C@H]1OC(COC(=O)c2ccccc2)[C@@H](OC(=O)c2ccccc2)[C@H](OC(=O)c2ccccc2)C1OC(=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 8/20 0.49
USP2 O75604 2/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
KMT2A Q03164 1/20 0.46
F11 P03951 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
TMPRSS2 O15393 1/20 0.45
PDE5A O76074 1/20 0.45
HMGCR P04035 1/20 0.45
CYP1A2 P05177 1/20 0.45
LCK P06239 1/20 0.45
FYN P06241 1/20 0.45
HSPD1 P10809 1/20 0.45
CYP2C9 P11712 1/20 0.45
CA6 P23280 1/20 0.45
TBXAS1 P24557 1/20 0.45
MAPK3 P27361 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15102739 1.00 PTPN1 (0.49) PTPN1USP2MEN1POLBKMT2A
SCHEMBL13250753 1.00 PTPN1 (0.49) PTPN1USP2MEN1POLBKMT2A
SCHEMBL17850336 1.00 PTPN1 (0.49) PTPN1USP2MEN1POLBKMT2A
SCHEMBL806155 1.00 PTPN1 (0.49) PTPN1USP2MEN1POLBKMT2A
SCHEMBL22946818 0.97 PTPN1 (0.50) PTPN1USP2MEN1POLBKMT2A
SCHEMBL32675078 0.97 PTPN1 (0.50) PTPN1USP2MEN1POLBKMT2A
SCHEMBL10177707 0.95 ANTXR2 (0.46) PTPN1USP2MEN1POLBKMT2A
SCHEMBL13447794 0.95 TSHR (0.47) PTPN1USP2MEN1POLBKMT2A
SCHEMBL13341003 0.92 PTPN1 (0.47) PTPN1USP2MEN1POLBKMT2A
SCHEMBL22455859 0.92 LGALS3 (0.43) PTPN1USP2MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344125-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2013-01-01 US disclosed
US-8106022-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
US-20100179309-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS (US) 2010-07-15 US disclosed
US-7674778-B2 Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine ALNYLAM PHARMACEUTICALS (US) 2010-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179309-A1 MODIFIED iRNA AGENTS HNRNPA0, HNRNPA1, SNRPA PTPN1 1606/4885USP2 4106/4885MEN1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.